Navigation Links
MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
Date:3/9/2009

obtain an immediate supply of insulin and the ability to supply our insulin needs for the future, even if we are unable to acquire the facility itself. We are pleased with this opportunity to secure our insulin supply, which brings AFRESA one step closer to commercial readiness."

Additional information about this transaction is available in a Current Report on Form 8-K filed by MannKind with the Securities and Exchange Commission earlier today.

About AFRESA(R)

AFRESA is an ultra rapid acting insulin product that has completed Phase 3 trials. The pharmacokinetic profile of AFRESA sets it apart from all other insulin products. The large surface area of the lung provides unique access to the circulatory system. The pH-sensitive AFRESA particles immediately dissolve upon contact with the lung surface, releasing insulin monomers that rapidly enter the bloodstream. It achieves peak insulin levels within 12-14 minutes of administration, effectively mimicking the release of meal-time insulin observed in healthy individuals, but which is absent from patients with diabetes.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press release as well as additional information about MannKind. Interested persons can subscri
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
2. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
3. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
4. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
5. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
6. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
7. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
8. MannKind to Present at the UBS Global Life Sciences Conference
9. MannKind Corporation Reports Second Quarter Financial Results
10. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
11. MannKind to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Mass. , July 1, 2015   ... most frequently cited advantages of Otezla are its ... safety profile, as reported by surveyed rheumatologists. Otezla ... launched for the treatment of active psoriatic arthritis ... The current standard of care includes conventional oral ...
(Date:7/1/2015)... BANGALORE, India , July 1, 2015 ... that uses next generation sequencing technology to empower cancer ... Storrer as chief executive officer. In his expanded ... responsible for all strategy, business expansion and worldwide operations ... served as Strand,s chairman and CEO since its founding ...
(Date:7/1/2015)... Bermuda , July 1, 2015  Axovant ... company focused on the treatment of dementia, today ... briefing on July 22 at 5:45 p.m. EDT ... the Alzheimer,s Association International Conference 2015 (AAIC). ... remarks: , Dr. Lawrence Friedhoff ...
(Date:7/1/2015)... ... 2015 , ... A newly launched business plan contest will ask startup companies ... in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small ... period of expert mentorship from a senior industry figure drawn from the Pistoia Alliance ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
... have been lionized in the press and academic circles ... performance and stellar financial results. While these leaders and ... management philosophies they represent and the practices they espouse ... and yank approach to pruning the bottom 10% of ...
... and Underwriters Laboratories have announced they will work ... tests for telecommunications suppliers. The tests cover ... transportation vibration, heat, humidity, and altitude. , , ... will provide customers of both companies access to ...
... It's easy to be fooled by first impressions. And I have ... to profile Confoti in the January 2002 issue of DEMOletter, I ... sold over the Internet. Dot-com businesses were imploding left ... supply site wouldn't be around for long. , ,I couldn't ...
Cached Biology Technology:Seven leadership lessons of Next Generation Companies 2Seven leadership lessons of Next Generation Companies 3Confoti: Revisiting a dotcom business model 2Confoti: Revisiting a dotcom business model 3Confoti: Revisiting a dotcom business model 4Confoti: Revisiting a dotcom business model 5
(Date:6/17/2015)... 17, 2015  Crossmatch™, a leading provider of ... U.are.U ® 4500 fingerprint readers have been ... Inc., a San Jose, CA ... security, improve accountability and reduce fraud at the ... identity confirmation for employee sign in and transaction ...
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue ... amount to at least 340 MSEK to that it will ... in market growth and orders received the revenue guidance for ... for 2015 will exceed 1,500 MSEK to an updated guidance ... Due to receipt of orders of touch fingerprint ...
(Date:6/12/2015)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announced the United States Patent ... and identify participants of a video visitation session ... system can: , Identify that the ... process is actually the person participating in the ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the ... Food and Drug Administration (FDA) on January 30, 2009 ... walking ability in people with multiple sclerosis (MS). The ... be subject to standard review, which would provide a ...
... Edible fungus foils dangerous grapefruit-drug interactions, Journal ... Florida report that adding an edible mushroom-like fungus to ... effects that can occur when people taking certain prescription ... January 14 edition of the ACS, bi-weekly Journal ...
... A drug used to improve blood flow to the ... the risk of Alzheimer,s disease, according to a new study ... (TGen) and Arizona State University. Fasudil has been used ... in stroke patients by dilating blood vessels when blood flow ...
Cached Biology News:Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis 2American Chemical Society's Weekly PressPac -- Jan. 28, 2009 2American Chemical Society's Weekly PressPac -- Jan. 28, 2009 3American Chemical Society's Weekly PressPac -- Jan. 28, 2009 4American Chemical Society's Weekly PressPac -- Jan. 28, 2009 5American Chemical Society's Weekly PressPac -- Jan. 28, 2009 6TGen and ASU researchers find drug that could reduce risk of Alzheimer's 2TGen and ASU researchers find drug that could reduce risk of Alzheimer's 3
... designed to provide a thin film-like barrier when a ... This barrier creates the proper surface tension to ... the slide. PAP Pen contains a special formulation ... can be removed, if desired, by xylene after the ...
... Signets FAST RED Chromogen System consists ... FAST RED reacts in the presence of ... minimal background noise. The FAST RED ... ,The System Contains: , , Vial ...
... F10 tubing kit provides high-pressure tubing ... system and other chromatography systems. The ... Tefzel, and orange PEEK tubing for ... basic chromatography system running at flow ...
... Miscellaneous: Versatile stain for staining RNA (bluish-purple), DNA (blue), ... TLC ≥ 90 % Cation traces: Ca ≤ ... mg/kg Cr ≤ 5 mg/kg Cu ≤ 5 mg/kg ... ≤ 5 mg/kg Mn ≤ 5 mg/kg Na ≤ ...
Biology Products: